Roots to Thrive
- 12 weekly virtual community of practice meetings
- Small group supported by two RTT facilitators – a Registered Therapist and Registered Nurse
- 3 ketamine-assisted therapy sessions with your small group
- Multiple integration and education sessions
- Physician referral required by a primary care physician (Family Doctor, Nurse Practitioner or treating Psychiatrist).
Program Cost: $5850 + tax
Roots to Thrive
- 8 weekly virtual community of practice meetings
- Small group supported by two RTT facilitators – a Registered Nurse and Registered Therapist
- 1 psilocybin-assisted therapy session with your small group
- Multiple education and integration sessions
- Physician referral required
Program Cost: $2800 + tax
Unique eligibility requirements exist for each of our programs
Roots to Thrive
- Substance use disorder
- Disordered eating
- Disordered sleep
- Uncontrolled or untreated hypertension (above 150/90)
- Some hepatic disorders (reviewed case by case)
- Some kidney disorders (reviewed case by case)
- Some vascular disorders (reviewed case by case)
- Presence of active psychotic symptoms
- Inability to tolerate group work
- Extreme emotional instability
- Ketamine allergy
- Medications that reduce the effectiveness of Ketamine:
Roots to Thrive
- Terminal diagnosis with limited life expectancy
- eGFR >20 ml/min
- AST < 3xULN and bilirubin <50 umol/L
- Emotional distress that has not successfully responded to other treatments: other treatments failed, patient could not tolerate other treatments, patient is unable to access other treatments, or patient refused other treatments for reasons acceptable to our treatment team.
- Patient demonstrates comprehension sufficient for understanding the consent form.
- Treatment in clinical trial where psilocybin would exclude patient from continuing to recieve treatment.
- Pregnancy or lactation
- Poorly controlled insulin-dependent diabetes
- Currently taking on a daily basis: investigational agents, or MAO inhibitors.
- Patients taking MAO-A inhibitors (especially the irreversible inhibitors) will require a minimum 2-week washout period. The possible concern over serotonin syndrome with these agents is not well documented in the literature, however the long interval before MAO is replenished may warrant a cautious approach based on the patient’s risk factors and warrants oversight from the MRP (Most Responsible Physician)
- Patients taking MAO-B inhibitors should be assessed on a case by case basis as there is a potential for a heightened response and warrants oversight from the MRP.
- Active uncontrolled epilepsy.
- Cancer has central nervous system involvement.
- Paraneoplastic syndrome or a tumor with ectopic hormone production which may place the patient at risk for hypercalcemia, Cushing’s syndrome, or SIADH secretion.
- Uncontrolled cardiovascular conditions: uncontrolled hypertension, uncontrolled angina, a clinically significant ECG abnormality (e.g. QT prolongation).
- Uncontrolled vascular disease (such as TIA in the last 3-6 months, stroke with loss in mental status, peripheral or pulmonary vascular disease with active claudication).
- Severity of depression or anxiety symptoms warranting immediate emergent treatment with antidepressant or daily anxiolytic medication (e.g., due to suicidal ideation) as these patients would require immediate referral to community psychiatry.
- Current or past history of meeting DSM-5 criteria for (the following diagnoses must have been confirmed by a qualified psychiatrist or psychologist):
- Psychotic Disorder (unless substance-induced or due to a medical condition);
- Borderline Personality Disorder;
- Bipolar I Disorder;
- Bipolar II Disorder;
- Other psychiatric conditions judged to be incompatible with establishment of rapport or safe exposure to psilocybin.
- Borderline Personality Disorder, Bipolar I Disorder and Bipolar II Disorder may be considered after a psychiatric consult.
- Bipolar I would require more in-depth investigation in relation to the history of manic episodes.
- Meet DSM-5 criteria for Dissociative Disorder
- Concurrent use of illicit drugs causing ongoing intoxication
- Unstable housing conditions (homelessness)
Conditions requiring special psychiatric consideration:
- First degree relatives meet DSM-5 criteria for Bipolar Disorder or Schizophrenia.
Click below to read our most recent research findings.
We work collaboratively with the participants’ primary mental health care provider to ensure collaborative safe care. This is a time limited program which compliments other forms of treatment. This is not a substitute for other forms of care and expect participants to maintain a relationship with their care team outside of Roots to Thrive including their referring provider.